Deferiprone

Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study^{[1][2][3][4][5][6][7][8]}. In Vitro:Deferiprone (66-660 μM, 48-96 h) has a significant inhibitory effect on proliferation in TRAMP-C2, Myc-CaP, and 22rv1 cells^[1].
Deferiprone (100 μM, up to 192 h) inhibits cell migration in TRAMP-C2, Myc-CaP, and 22rv1 cells^[1].
Deferiprone (100 μM, 24 h) reduces the expression and activity of m-Acon in TRAMP-C2, Myc-CaP, and 22rv1 cells^[1].
Deferiprone (up to 1μM, 0.5-24 h) decreases the free iron in thalassemic red blood cells^[2].
Deferiprone (10 mins) inhibits human platelet aggregation stimulated by AA and ADP and epinephrine and collagen, with the IC₅₀ values of 0.24, 0.25, 3.36 and 3.73 mM, respectively^[3].
Deferiprone (0.1-3.2 μM, 5 mins) inhibits COX-1 activity with the IC₅₀ value of 0.33 μM^[3].
Deferiprone (4 mM, 5 mins) preventes ADP-induced formation of cAMP^[3].
Deferiprone (156.25 μg/mL, 24 h) enhances survival rate and reduces LDH Levels and displays normal cell morphology in aged Fibroblasts^[4].
Deferiprone (25μM, 6 h) amplifies the antibacterial activity of conventional antibiotics against S. epidermidis^[5]. In Vivo:Deferiprone (100 mg/kg/daily for i.g., 4 weeks) has a neuroprotective effect in the rTg(tauP301L)4510 mouse model of tauopathy^[6].
Deferiprone (50-200 mg/kg/daily for p.o., 5-10 day) reduces the nephrotoxicity in Cisplatin (HY-17394)-induced rat acute renal failure^[7].
Deferiprone (13.82, 27.64 mg/kg/d for i.g., 4 weeks) exhibits anti- apoptosis and neuroprotective activity in rat Alzheimer’s disease model^[8].